Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, health state utility values revealed a significant impact on quality of life for patients with alopecia areata, particularly those with more extensive hair loss.

This study reported that the most reliable way to differentiate alopecia areata from androgenic alopecia is by detecting intrafollicular CD3 and CD8 cell density, with CD3 being the most specific and sensitive marker.

This study found that dermatologists in the southeastern U.S. often offer less frequent treatment for children with alopecia areata compared to adults, with more treatment also recommended for more advanced stages of hair loss.

This study observed no significant difference in vitamin D levels between children with alopecia areata and controls, but higher complete improvement in alopecia was noted among patients with vitamin D deficiency undergoing oral vitamin D treatment.

This case report described a five-year-old girl with alopecia areata totalis who experienced significant hair regrowth after receiving dental rehabilitation for extensive untreated caries and chronic oral infection, suggesting a possible link between chronic oral infection and alopecia areata.

This study found that while the global incidence of alopecia areata in individuals aged 0–19 declined from 1990-2021, the total number of cases rose, with higher burdens among females, adolescents, and low-SDI populations, particularly in Central Sub-Saharan Africa; disparities suggest a need for targeted interventions.

This study reviewed existing literature to provide comprehensive insights into diagnosing and managing alopecia areata, emphasizing the importance of understanding its classification, etiology, and the diverse treatment options available for improved patient care.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

In this phase 3 trial, baricitinib showed effectiveness and safety in both adolescents and adults with severe alopecia areata, with adolescents achieving higher response rates despite more severe baseline conditions, suggesting the advantages of early treatment.

In this case study, a 10-year-old girl with infantile ophiastic alopecia areata and ciliary madarosis showed excellent hair and eyelash regrowth after 56 days of treatment involving oral corticosteroids, topical minoxidil, and clobetasol hair lotion, following an initial diagnosis and psychological evaluation.

This review highlights the variability and unpredictability of alopecia areata, ranging from single scalp patches to total body hair loss, and notes the 2022 approval of the first AA-specific drug, baricitinib, potentially spurring new research into targeted treatments.

This review explores the causes and mechanisms of alopecia areata and discusses current treatments, reporting no new clinical findings.

The researchers reported that both cryotherapy and betamethasone lotion yielded similar improvement rates for alopecia areata patches, without complete recovery observed in any patient.

The researchers reported that pubic hair transplantation surgery may help improve self-esteem in women with pubic atrichosis or hypotrichosis by achieving natural and realistic-looking results.

This study suggested that pubic hair transplantation surgery can effectively address feelings of inferiority in patients with pubic atrichosis or hypotrichosis, achieving a mean graft survival rate of 73.6%.

This study investigated the safety and effectiveness of two thioglycolate chemical depilatory creams for full genital hair removal in men and women, finding acceptable dermal tolerance despite some instances of irritation, supporting their use for pubic hair grooming.

This study found that pubic skin fibroblasts respond to androgens, increasing 5α-reductase activity via an androgen receptor-mediated mechanism, suggesting its potential as a marker of androgen action in vitro.

In this study, vitiligo and alopecia areata were more common among patients with chronic graft-vs-host disease than previously reported, linked to higher NIH skin scores and greater immunosuppressive treatment.

The cause of alopecia areata was unknown, and while various treatments existed, no best treatment was agreed upon.

This case report describes a 42-year-old woman with atopic dermatitis, whose alopecia areata reactivated rapidly after starting dupilumab, possibly indicating an unrecognized adverse effect in AD patients.

This report presents evidence that alopecia areata incognita may be a possible mechanism of hair loss in patients with Cronkhite–Canada syndrome.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

In this study, traditional treatment for pediatric alopecia areata was highly effective, with all patients achieving full hair regrowth. Tofacitinib and microneedling were less effective but are viable options for severe cases, while adverse effects were mild across all treatments.

In this case report, individualized homeopathic treatment based on symptom totality led to anxiety reduction, halted lesion progression, and complete cosmetic recovery in a 30-year-old male with alopecia areata barbae, highlighting a potential area for further controlled studies.

This review examines various pharmacological options for managing alopecia areata, highlighting the effectiveness of corticosteroids for mild to moderate cases and promising results from JAK inhibitors like baricitinib for more severe forms, with additional benefits from minoxidil and potential from other treatments.

In this study, Erianin was found to significantly suppress alopecia areata in a mouse model by inhibiting effector T cell function, reversing systemic symptoms, and promoting hair growth.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

This abstract discusses alopecia areata, highlighting its complex autoimmune pathogenesis involving immune cells and signaling molecules, and underscores the importance of accurate diagnosis and tailored management strategies, noting the need for further research to improve treatments.

This study found that yellow dots seen under dermatoscopy are a sensitive and specific indicator of treatment response in alopecia areata, showing significant reduction as early as four weeks.

This review summarizes methods for creating alopecia areata animal models and reports no new results, emphasizing that improved evaluation and combined disease models are needed for future research.